Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with cancer of cervix~* tumor that can be measured~* no previous treatment with chemotherapy or radiation for this cancer~* Karnofsky Performance Status Score \>=70~* able to give written consent~* willing and able to participate in the study, both during the active treatment and the follow-up period.~Exclusion Criteria:~* impairment such as hearing loss from prior cisplatin therapy~* damage to nerves such as being unable to distinguish hot and cold to touch~* used other experimental medication in past 30 days~* lab test results are not within the limits required for this study~* pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth control.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week~Two week rest period with no chemotherapy or radiation~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
- 2 (Type: ACTIVE_COMPARATOR): Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week

Based on this trial design, predict the completion outcome and termination type (if applicable).